Mankind Pharma reports Q4 FY26 revenue growth of 12%
after close1 source ↓written by the desknot a recommendation
- reaching
- ₹3,443 cr
- EBITDA surged
- 36.1%
- ₹930 cr
- from 22.2
- 27%
- net profit
- ₹420.8 cr
Mankind Pharma posted Q4 FY26 revenue growth of 11.8% YoY, reaching ₹3,443 cr. EBITDA surged 36.1% to ₹930 cr, with an EBITDA margin expansion to 27% from 22.2%. Despite a slight dip in net profit to ₹420.8 cr, the results reflect strong domestic performance, impacting market sentiment positively.
Not investment advice. For informational purposes only.